Keen Vision Acquisition Corporation Ordinary Shares
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KVAC research report →
Price Chart
About the company
Keen Vision Acquisition Corporation (KVAC) is a firm founded with the primary objective of finalizing a substantial business transaction. This could involve, but is not limited to, a merger, an equity exchange, an asset acquisition, a share purchase, a capital reordering, or a corporate restructuring, with one or more external entities. KVAC strategically concentrates its efforts on identifying and collaborating with companies operating within the biotechnology, consumer product, and agricultural industries.
- CEO
- Ka Chun Wong
- IPO
- 2023
- Employees
- 2
- HQ
- Summit, NJ, US
Get TickerSpark's AI analysis on KVAC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $106.33M
- P/E
- 108.28
- PEG
- -2.00
- P/S
- 0.00
- P/B
- -1.65
- EV/EBITDA
- -173.45
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 3.50%
- ROIC
- -7.00%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-743,509
- Net Income
- $1.91M-74.2%
- EPS
- $0.19-65.5%
- OCF Growth
- +31.4%
- FCF Growth
- +31.4%
- 52W High
- $18.72
- 52W Low
- $11.00
- 50D MA
- $12.28
- 200D MA
- $12.01
- Beta
- -0.00
- RSI (14)
- 46
- Avg Volume
- 6.46K
No earnings-call transcripts are available for KVAC yet.
- Free Float
- 77.2%
- Shares Outstanding
- 9.24M
- Float Shares
- 7.13M
of shares held by institutions
13 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mizuho Securities Usa LLC | 295.22K | 0 |
| Quarry LP | 149.48K | ▼ 11 |
| Rlh Capital LLC | 149.48K | ▼ 78.77K |
| Berkley W R Corp | 100.18K | ▲ 180 |
| Calamos Advisors LLC | 100.00K | 0 |
| Glazer Capital, LLC | 99.90K | 0 |
| Aqr Arbitrage LLC | 87.08K | 0 |
| Clear Street Group Inc. | 70.78K | ▼ 9.54K |
| Toronto Dominion Bank | 43.90K | ▲ 43.90K |
| Penderfund Capital Management Ltd. | 32.00K | ▲ 32.00K |
| Jane Street Group, LLC | 12.36K | ▲ 170 |
| Geode Capital Management, LLC | 11.18K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 24, 23 | Ding Yibing | other | 0 |
| Jul 24, 23 | Li Ronald Adolphus | other | 0 |
| Jul 24, 23 | KVC Sponsor LLC | other | 0 |
| Jul 24, 23 | Wong Ka Chun Kenneth | other | 0 |
| Jul 24, 23 | Davidkhanian Alex | other | 0 |
| Jul 24, 23 | Yu Albert Cheung-Hoi | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KVAC coverage
Recent articles, reports, and earnings notes.
No research on KVAC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KVAC report →Financial Comparison: Blaize (NASDAQ:BZAI) and Keen Vision Acquisition (NASDAQ:KVAC)
defenseworld.net · Apr 15
Keen Vision Acquisition (NASDAQ:KVAC) Shares Up 0.9% – Here’s What Happened
defenseworld.net · Apr 14
65,256 Shares in Keen Vision Acquisition Corporation $KVAC Acquired by Crossingbridge Advisors LLC
defenseworld.net · Mar 9
Keen Vision Acquisition (NASDAQ:KVAC) Stock Price Up 0.1% – Time to Buy?
defenseworld.net · Feb 21
Keen Vision Acquisition (NASDAQ:KVAC) Trading 0.5% Higher – Still a Buy?
defenseworld.net · Nov 22
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025
globenewswire.com · Jun 13
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
globenewswire.com · May 12
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
globenewswire.com · Apr 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.